Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877801 | 0.86 | GAA (0.66) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL27783744 | 0.84 | GAA (0.53) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL581026 | 0.81 | GAA (0.67) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL30683883 | 0.79 | GAA (0.64) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL8806160 | 0.79 | GAA (0.69) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL29113608 | 0.79 | GAA (0.64) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL29805515 | 0.78 | KDM4E (1.00) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL29805317 | 0.78 | GAA (0.67) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL6125360 | 0.78 | HPGD (0.68) | GAAKDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL15392283 | 0.78 | GAA (0.62) | GAAKDM4EPOLBHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103012390-B | As the indole derivatives of S1P1 receptor stimulant | GLAXO GROUP LTD. (GB) | 2015-08-26 | — | — | CN | disclosed |
| CN-101663297-B | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103012390-A | Indole derivatives as S1P1 receptor | GLAXO GROUP LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| CN-101611033-B | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD | 2012-10-31 | — | — | CN | disclosed |
| EP-2206710-B1 | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| CN-101663297-A | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2010-03-03 | — | — | CN | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| CN-101611033-A | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | GAA 3538/4885KDM4E 3695/4885POLB 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.